OS Therapies Inc
OSTX · XNYSCIK 1795091fmd_0BPN7EFEDRPZ8HY7JWS2APWF23Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Jun 30, 2026, 14 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Research and development | 3 | 3 | 16 |
| Operating income | (4) | (7) | (29) |
| Interest expense | 3 | 2 | – |
| Interest and investment income | 0 | – | 0 |
| Other non-operating income (expense) | (3) | (2) | (0) |
| Net income | (8) | (9) | (29) |
| Net income to common shareholders | (8) | (9) | (29) |